linvemastat

Phase 2Small molecule

FForesee Pharmaceuticals Co., Ltd.

linvemastat is one of 3 small molecule programs targeting Asthma (Diagnosis). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Asthma (diagnosis)Not yet recruiting

Asthma (diagnosis)Phase 2

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Asthma (diagnosis)

#DrugCompanyPhaseTrials

KT-621

KKymera Therapeutics, Inc.

Phase 2

1 2

linvemastat

FForesee Pharmaceuticals Co., Ltd.

Phase 2

1 3

ETH47

EEthris GmbH

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Asthma (diagnosis)

NCT07191535

Clinical

Trials by Indication[1]

Asthma (Diagnosis)1 trial

A Multinational Randomized Double-Blind Placebo-Controlled Phase 2 Study to Evaluate the Effect of Linvemastat (FP-020) in Patients With Partially Controlled Asthma on Inhaled Corticosteroids and Long-Acting Beta-Agonists (syMMPonia Study)

Not yet recruiting·FForesee Pharmaceuticals Co., Ltd.·Phase 2·NCT07191535·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for linvemastat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — linvemastat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for linvemastat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Foresee Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FForesee Pharmaceuticals Co., Ltd.

linvemastat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Asthma (Diagnosis)1 trial

References

Drug Info

Quick Facts

Related News